OLMA

SAN FRANCISCO, April 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present initial clinical data from the Phase 1 study of OP-3136 in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29-June 2 in Chicago, Illinois. The Company will also present a trial-in-progress poster for the Phase 3 OPERA-02 trial. Poster Presentation Details Title: A phase 1, first-in-human study of OP-3136, a novel oral selectiv

Palazestrant's mechanism of action confirmed; full recruitment of corepressor protein NCoR1 enables complete antagonism of the estrogen receptorOP-3136, in combination with palazestrant, exhibits synergistic anti-tumor activity in ER+/HER2- breast cancer models driven by suppression of cell-cycle and estrogen receptor-driven oncogenic signalingPalazestrant is currently being evaluated in two Phase 3 clinical trials; OP-3136 is enrolling patients in the ongoing Phase 1 study SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercia

SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 188,500 shares of the Company's common stock, effective as of April 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance

Wolfe Research initiated coverage of Olema Pharmaceuticals with a rating of Peer Perform

Jefferies resumed coverage of Olema Pharmaceuticals with a rating of Buy

SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present two preclinical posters at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22 in San Diego, California. Poster Presentation Details Title: Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alphaPoster/Abstract: 2950Session: Experimental and Molecular Therapeutics: Cellular

144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

S-8 - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

10-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancerAdvanced enrollment in the OPERA-02 pivotal Phase 3 trial of palazestrant in combination with ribociclib in patients with frontline ER+/HER2- metastatic breast cancer Initiated the Phase 1b/2 study of palazestrant in combination with Pfizer's novel CDK4 inhibitor, atirmociclib, in patients with ER+/HER2- metastatic breast cancerContinued enrollment in the Phase 1 clinical study of OP-3136 in breast cancer and other solid tumors, with initial clinical data expected in Q2 2026Generated $218.5 million in gross proce

144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

SCHEDULE 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 205,000 shares of the Company's common stock, effective as of March 2, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance

144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)